Home › NCT06653426
The NaBu Effect on Menstruation in Women
Recruiting
The Effect of Sodium Butyrate on Menstrual Symptoms in Women
Who can join
Ages 18 and older · Women
Full eligibility criteria
Inclusion Criteria: * 18 years or older. * Menstruating regularly or irregularly * Experiencing menstrual symptoms with an average baseline symptom score of at least 3 on a scale of 0 to 10 for at least one symptom during the initial pre-study rating period. Exclusion Criteria: * Pregnant or breastfeeding patient, attempting or anticipating pregnancy. * Patient with a history of bloating or a sensitive gut (food intolerance) who needs lower fiber levels. * Patients with known lactose intolerance, other fermentable oligo-, di-, and mono-saccharides, and polyols (FODMAP) intolerances, or small intestinal bacterial overgrowth (SIBO). * Patients who would require taking daily antacids for the duration of the study. * Patients with known or suspected chronic hypertension. * Post-menopausal patients
About the study
The purpose of this study is to evaluate the effect of once-daily Sodium butyrate (NaBu) on menstrual symptoms in women. The investigators posit that the use of NaBu will reduce menstrual symptoms after taking NaBu for 12 weeks.
What is being tested
- Sodium Butyrate (NaBu) (dietary supplement)
Sponsor: Magdy Milad, MD · Participants: 15 · Started: Oct 1, 2024
Contact the study team
- juan A avitia, MS · Phone: 312-694-6447
Official record on ClinicalTrials.gov — NCT06653426
Locations in the U.S.
| Illinois | Northwestern University - Northwestern Medicine, Lavin Family Pavilion, Chicago |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.